1. Angell M, JP. K. Alcohol and other drugs-toward a more rational and consistent policy. N Engl J Med. 1994; 331:537-539.
2. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev. 2011:Cd008537.
3. Calcaterra NE, Barrow JC. Classics in chemical neuroscience: diazepam (valium). ACS Chem Neurosci. 2014; 5:253-260.
4. Parthasarathy R, Kattimani S, Sridhar MG. Oxidative stress during alcohol withdrawal and its relationship with withdrawal severity. Indian J Psychol Med. 2015; 37:175-180.
5. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998; 49:173-184.
6. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 1998; 82:107-114.
7. Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry. 1998; 155:726-732.
8. Chen J, Shang X, Hu F, Lao X, Gao X, Zheng H, et al. beta-Lactamase inhibitors: an update. Mini Rev Med Chem. 2013; 13:1846-1861.
9. Nakagawa H, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T. Penetration of potassium clavulanate/ticarcillin sodium into cerebrospinal fluid in neurosurgical patients. Jpn J Antibiot. 1994; 47:93-101.
10. Rawls, SM, Karaca F, Madhani I, Bhojani V, Martinez RL, Abou-Gharbia M, et al. Beta-lactamase inhibitors display anti-seizure properties in an invertebrate assay. Neuroscience 2010;169:1800-1804.
11. Kim DJ, King JA, Zuccarelli L, Ferris CF, Koppel GA, Snowdon CT, et al. Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacol Biochem Behav. 2009; 93:112-120.
12. Sanna F, Melis MR, Angioni L, Argiolas A. Clavulanic acid induces penile erection and yawning in male rats: comparison with apomorphine. Pharmacol Biochem Behav. 2013; 103:750-755.
13. Huh Y, Ju MS, Park H, Han S, Bang Y-M, Ferris CF, et al. Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases. Drug Develop Res. 2010; 71:351–357.
14. Schroeder JA, Tolman NG, McKenna FF, Watkins KL, Passeri SM, Hsu AH, et al. Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug? Drug Alcohol Depend. 2014; 142:41-45.
15. Davidson M, Chen, WB and Wilce, PA Behavioral analysis of PTZ-kindled rats after acute and chronic ethanol treatments. Pharmacol Biochem Behav. 1999; 64: 7-13.
16. Scott-Stevens P, Atack JR, Sohal B, Worboys P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm Drug Dispos. 2005; 26:13-20.
17. Jung ME, Metzger DB. Alcohol withdrawal and brain injuries: beyond classical mechanisms. Molecules 2010; 15:4984-5011.
18. National, Research, Council. Guide for the care and use of laboratory animals. Washington: National Academy Press; 1996.
19. Shoja M, Mehri S, Amin B, Askari VR, Hosseinzadeh H. The prophylactic and therapeutic effects of saffron extract and crocin on ethanol withdrawal syndrome in mice. J Pharmacopuncture 2018; 21:277-283.
20. Ruby B, Benson MK, Kumar EP, Sudha S, Wilking JE. Evaluation of Ashwagandha in alcohol withdrawal syndrome. Asian Pacific J Trop Dis. 2012; 2:S856-S860.
21. Denenberg VH. Open-field behavior in the rat: what does it mean? Ann N Y Acad Sci. 1969;159:852-859.
22. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protocols. 2007; 2:322-328.
23. Hamm RJ, Pike BR, O’Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma. 1994; 11:187-196.
24. Becker A, Grecksch G, Brosz M. Antiepileptic drugs--their effects on kindled seizures and kindling-induced learning impairments. Pharmacol Biochem Behav. 1995; 52:453-459.
25. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978; 86:271-278.
26. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979; 582:67-78.
27. Gasior M, Socala K, Nieoczym D, Wlaz P. Clavulanic acid does not affect convulsions in acute seizure tests in mice. J Neural Transm. 2012; 119:1-6.
28. Gonzaga NA, Mecawi AS, Antunes-Rodrigues J, De Martinis BS, Padovan CM, Tirapelli CR. Ethanol withdrawal increases oxidative stress and reduces nitric oxide bioavailability in the vasculature of rats. Alcohol 2014; 49:47-56.
29. Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol.1990; 176:289-296.
30. Rao PS, Bell RL, Engleman EA, Sari Y. Targeting glutamate uptake to treat alcohol use disorders. Front Neurosci. 2015; 9:144.
31. Abulseoud OA, Camsari UM, Ruby CL, Kasasbeh A, Choi S, Choi DS. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology 2014; 39:1674-1684.
32. Kim J, John J, Langford D, Walker E, Ward S, Rawls SM. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice. Amino Acids 2016; 48:689-696.
33. Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB. Clavulanic acid inhibits MPP(+)-induced ROS generation and subsequent loss of dopaminergic cells. Brain Res. 2012; 1469:129-135.
34. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem 2007; 100:857-873.
35. Lal H, Prather PL, Rezazadeh SM. Potential role of 5HT1C and/or 5HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res. 1993; 17:411-417.
36. Connor H. Serotonin syndrome after single doses of co-amoxiclav during treatment with venlafaxine. J R Soc Med. 2003; 96:233-234.
37. Rosland JH, Hunskaar S, Hole K. Diazepam attenuates morphine antinociception test-dependently in mice. Pharmacol Toxicol. 1990; 66:382-386.
38. Batlle JF, Arranz EE, de Castro Carpeño J, Sáez EC, Auñón PZ, Sánchez AR, et al. Oral chemotherapy: potential benefits and limitations. Revista Oncología. 2004; 6:335-340.